First Trust Advisors LP Has $4.79 Million Stake in GeneDx Holdings Corp. $WGS

First Trust Advisors LP increased its position in shares of GeneDx Holdings Corp. (NASDAQ:WGS) by 20.2% during the 1st quarter, HoldingsChannel reports. The fund owned 74,602 shares of the company’s stock after purchasing an additional 12,552 shares during the quarter. First Trust Advisors LP’s holdings in GeneDx were worth $4,791,000 at the end of the most recent quarter.

Several other hedge funds have also added to or reduced their stakes in the company. Royal Bank of Canada boosted its stake in shares of GeneDx by 30.2% in the 1st quarter. Royal Bank of Canada now owns 29,479 shares of the company’s stock valued at $2,611,000 after purchasing an additional 6,840 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in shares of GeneDx by 6.3% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 7,641 shares of the company’s stock worth $677,000 after buying an additional 453 shares during the last quarter. NewEdge Advisors LLC lifted its holdings in GeneDx by 270,700.0% in the first quarter. NewEdge Advisors LLC now owns 2,708 shares of the company’s stock valued at $240,000 after buying an additional 2,707 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in GeneDx by 67.5% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 28,224 shares of the company’s stock valued at $2,500,000 after buying an additional 11,375 shares during the period. Finally, Cetera Investment Advisers acquired a new position in GeneDx in the second quarter valued at approximately $249,000. Institutional investors own 61.72% of the company’s stock.

GeneDx News Roundup

Here are the key news stories impacting GeneDx this week:

• Positive Sentiment: Analysts raised their outlook. Canaccord Genuity lifted its price target from $75 to $90 and assigned a “buy” rating. BTIG Research also reaffirmed its “buy” rating with a $90 target, implying substantial upside from recent trading levels. Canaccord raises GeneDx price target
• Positive Sentiment: Second-quarter adjusted earnings and revenue exceeded estimates. GeneDx reported adjusted EPS of $0.01 versus the consensus estimate of a $0.19 loss, while revenue reached $114.4 million, ahead of expectations near $111 million. Revenue increased about 11% year over year, and gross profit rose to $78.2 million. GeneDx Q2 earnings and revenue results
• Neutral Sentiment: Full-year revenue guidance was maintained. GeneDx reiterated 2026 revenue guidance of $475 million to $490 million, broadly in line with the roughly $477 million analyst consensus. Management expects a meaningful improvement in collections beginning in the fourth quarter, a potential catalyst if achieved. GeneDx reaffirms 2026 revenue guidance
• Negative Sentiment: Profitability and liquidity remain concerns. Despite the adjusted EPS beat, GeneDx reported a $17.5 million operating loss, a $17.7 million net loss attributable to common shareholders and $29 million of operating cash outflow. The company ended the quarter with $60.3 million in cash.
• Negative Sentiment: Shareholder litigation adds uncertainty. Several law firms publicized a securities class action alleging investor harm during an April 2025–May 2026 class period. The allegations have not been proven, but the case could create legal costs and reputational risk. GeneDx shareholder class action

GeneDx Stock Up 4.5%

Shares of WGS stock opened at $70.90 on Wednesday. The firm’s fifty day moving average price is $61.51 and its two-hundred day moving average price is $69.06. The company has a current ratio of 3.09, a quick ratio of 2.95 and a debt-to-equity ratio of 0.38. GeneDx Holdings Corp. has a 1 year low of $32.21 and a 1 year high of $170.87. The firm has a market capitalization of $2.11 billion, a P/E ratio of -26.46 and a beta of 1.92.

GeneDx (NASDAQ:WGS) last released its earnings results on Monday, August 3rd. The company reported $0.01 earnings per share for the quarter, beating the consensus estimate of ($0.19) by $0.20. The business had revenue of $114.44 million during the quarter, compared to analysts’ expectations of $111.01 million. GeneDx had a negative net margin of 23.41% and a positive return on equity of 3.97%. During the same period last year, the business earned $0.36 earnings per share. On average, equities analysts predict that GeneDx Holdings Corp. will post -1 EPS for the current fiscal year.

Insider Activity at GeneDx

In related news, Director Casdin Capital, Llc acquired 185,000 shares of the company’s stock in a transaction on Tuesday, May 19th. The stock was purchased at an average cost of $42.60 per share, with a total value of $7,881,000.00. Following the acquisition, the director directly owned 3,367,164 shares of the company’s stock, valued at approximately $143,441,186.40. The trade was a 5.81% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Keith A. Meister bought 533,758 shares of the firm’s stock in a transaction on Thursday, May 7th. The stock was purchased at an average cost of $37.86 per share, for a total transaction of $20,208,077.88. Following the completion of the acquisition, the director owned 3,761,908 shares in the company, valued at approximately $142,425,836.88. This trade represents a 16.53% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. In the last ninety days, insiders bought 2,256,420 shares of company stock worth $93,144,340 and sold 19,135 shares worth $1,128,499. 25.17% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of research analysts have recently weighed in on the company. Craig Hallum reissued a “buy” rating and issued a $85.00 price target on shares of GeneDx in a research note on Tuesday, May 5th. Canaccord Genuity Group lifted their price objective on GeneDx from $75.00 to $90.00 and gave the stock a “buy” rating in a research note on Tuesday. Weiss Ratings downgraded GeneDx from a “sell (d-)” rating to a “sell (e+)” rating in a report on Monday, June 1st. Wells Fargo & Company reissued an “overweight” rating and issued a $75.00 target price (down from $155.00) on shares of GeneDx in a research note on Tuesday, May 5th. Finally, Zacks Research upgraded GeneDx from a “strong sell” rating to a “hold” rating in a report on Tuesday, July 28th. Seven investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $89.57.

About GeneDx

GeneDx is a clinical diagnostics company specializing in comprehensive genetic and genomic testing for rare and inherited disorders. The company offers a broad portfolio of assays, including targeted gene panels, whole exome sequencing, whole genome sequencing and chromosomal microarray analysis. GeneDx’s laboratory services support the diagnosis of a wide range of conditions—from rare pediatric diseases and hereditary cancer syndromes to neuromuscular and metabolic disorders—by providing clinicians with detailed variant interpretation and reporting.

Founded in 2000 and based in Gaithersburg, Maryland, GeneDx was established with the aim of accelerating the translation of genomic discoveries into clinical care.